title: Sensitivity of human laryngeal squamous cell carcinoma Hep-2 to metrotexate chemoterapy.
abstract: OBJECTIVE
  Methotrexate (MTX) is an antifolate agent that acts inhibiting purine and pyrimidine synthesis. The objective of the study was to evaluate the viability of Hep-2 human laryngeal cancer cells to the treatment with MTX chemotherapy in vitro.
  
  
  METHODS
  Cultured Hep-2 cells were treated with 0.25, 25.0 and 75 μM MTX for 24 h, and their viability was evaluated with Bcl-2-FITC antibody in flow cytometry.
  
  
  RESULTS
  The numbers of viable Hep-2 cells after 24 h treatment with 0.25, 25.0 and 75.0 uM MTX were 85.43%, 22.46% and 8.42%, respectively (p < 0.05). Therefore, MTX possesses a dose-dependent effect on viability of Hep-2 cells in vitro.
  
  
  CONCLUSIONS
  The highest MTX concentration is associated with highest tumor cell sensitivity of human laryngeal cancer cells of Hep-2 line.
authors.affiliation: Genetics and Molecular Biology Research Unit, Upgem, FAMERP, São José do Rio Preto Medical School, Brazil. analivia_sg@yahoo.com.br
authors.forename: A L S
authors.initials: AL
authors.lastname: Galbiatti
authors.forename: H C
authors.initials: HC
authors.lastname: Caldas
authors.forename: J A
authors.initials: JA
authors.lastname: Padovani
authors.forename: E C
authors.initials: EC
authors.lastname: Pavarino
authors.forename: E M
authors.initials: EM
authors.lastname: Goloni-Bertollo
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002294:Carcinoma, Squamous Cell; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D005434:Flow Cytometry; D006801:Humans; D007822:Laryngeal Neoplasms; D008727:Methotrexate / Q000008:administration & dosage*
chemical_list: D000970:Antineoplastic Agents; D008727:Methotrexate